Elemental IV

Elemental IV is establishing Australia’s first modular GMP sterile manufacturing facility purpose-built to secure sovereign control over critical IV fluids, Water for Injection (WFI), and Ready-To-Use (RTU) compounded medicines.

The facility will locally manufacture high-volume IV fluids (saline, irrigation, WFI) alongside higher-value RTU electrolytes, antibiotics, and sedatives — reducing Australia’s reliance on imported sterile products and strengthening national health security across hospitals, defence, emergency services, and aged care.

Backed by industry experts in GMP, validation, aseptic compounding, and sterile manufacturing, Elemental IV combines pharmaceutical-grade capability with a capital-efficient modular design that enables rapid scale-up and resilient domestic production aligned with Australia’s sovereign manufacturing goals.

Investment Highlights

• Sovereign Capability:
  Australia’s first vertically integrated sterile fluids and RTU compounding facility purpose-built to reduce dependence on overseas suppliers.
• Large Market Gap:
  Over 80% of IV saline, WFI, and RTU injectable products used in Australia are imported, with multiple SKUs dependent on a single offshore manufacturer.
• Government-Aligned:
  Strong alignment with National Reconstruction Fund (NRF), state resilience initiatives, Defence Health procurement priorities, and emergency preparedness programs.
• Validated Demand:
  Early engagement and active interest from state hospitals and multiple private hospital groups.
• Modular GMP Facility:
  A scalable, capital-efficient manufacturing model enabling staged expansion across fluids and RTU compounds, supported by Epic Medical’s integrated filling technology.
• Balanced Economics:
  Stable baseline margins on saline and WFI, with significant uplift from high-margin RTU electrolytes, antibiotics, and sedative products.
• De-risked Investment Structure:
  Equipment secured under PPSR, clear validation milestones, staged commissioning, and eligibility for government co-investment reduce investor exposure.
• Specialist Leadership:
  Led by experts in sterile manufacturing, validation, QA/RA, and pharmaceutical operations (including experience from Pfizer, Hospira, BioCina, aseptic compounding and GMP facility deployments).